Taiwan Lipsome Company (TLC) Announces Proposed ADS IPO

Taiwan Liposome Company, Ltd. (NASDAQ: TLC), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of medical need in pain management, ophthalmology, and oncology, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering in the United States of its American Depositary Shares (ADSs) representing shares of common stock. All ADSs to be sold in the offering will be offered by TLC. The number of ADSs to be offered and the price for the proposed offering have not yet been determined. TLC has applied to list its ADSs on The Nasdaq Global Market under the trading symbol "TLC".

Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. CLSA Limited, H.C. Wainwright & Co., LLC, Janney Montgomery Scott LLC, and Laidlaw & Company (UK) Ltd. are acting as co-managers.

The proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor New York, New York 10022; Email: [email protected].

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• Kairos Pharma announces 1-for-7 reverse stock split
• SEC accuses ex-BofA senior banker Satsky of insider trading - Bloomberg